Cellnovo (EPA:CLNV) and Diabeloop said this week they are launching a CE Mark cross-over registration study for an artificial pancreas device Diabeloop is developing which uses Cellnovo’s insulin pump. The registration study aims to generate appropriate security & safety data as the company seeks CE Mark approval for the Diabeloop artificial pancreas combined with Cellnovo’s CGM some […]
Cellnovo (EPA:CLNV) said today that it has filed for 510(k) clearance from the FDA for its diabetes management system. Paris-based Cellnovo touts its system as the 1st mobile, connected diabetes management system. Tubeless and compact, the company’s insulin pump has a mobile touchscreen controller with an integrated blood glucose meter. Data from insulin injections and blood-glucose levels are […]
Cardiac Dimensions said this week that it tapped the former chief of AccessClosure, Gregory Casciaro, to be its new president & CEO. Casciaro led AccessClosure until its May 2014 acquisition by Cardinal Health (NYSE:CAH) for $320 million. His résumé includes stints as the chief executive at drug-eluting stent maker Xtent, Orquest (acquired JNJ’s DePuy Acromed in 2003) […]
MASSDEVICE ON CALL — Most small medical device companies may deal with the added burden of the impending 2.3% medical device tax by passing the cost onto customers, an industry survey found.
Of 180 device industry executives surveyed, about 75% of which represent companies with fewer than 50 employees, more than half reported that they plan to increase prices for their products in order to fully or partially offset the effects of the levy.
Eric Bouvier took over the corner office at BG Medicine (NSDQ:BGMD) yesterday as president & CEO of the Waltham, Mass.-based diagnostics developer.
Prior to joining BG, Bouvier, 51, headed the Immunoassay business at global diagnostics company BioMérieux. He also held the role of president & CEO of BioMérieux’s U.S. subsidiary bioMerieux Inc.
London-based diabetes device maker Cellnovo inked a pact with J&J-owned LifeScan Inc. to incorporate that company’s technology into Cellnovo’s flagship mobile diabetes management system.
Cellnovo will integrate LifeScan’s blood glucose monitoring technology into the handset of its mobile system – an insulin patch pump and a touch screen that wirelessly transmits real-time data to a secure portal available to patients and doctors.
CELLNOVO FORMS WORLDWIDE TECHNOLOGY ALLIANCE WITH LIFESCAN
CellnovoSeptember 13, 2011, London, UK. Press Dispensary. Cellnovo, developer of the first mobile diabetes management system, today announced a technology alliance with LifeScan, Inc. that will bring new portability and control to diabetes patients worldwide.
Under the global agreement, Cellnovo will integrate LifeScan’s blood glucose monitoring technologies into the handset of its mobile diabetes management system. The Cellnovo system, the first of its kind, consists of an insulin patch pump and a touch screen handset that wirelessly transmits real-time data to a secure portal for patients and healthcare providers to use.